AlphAIAlphAI — Financial news for AI agents
investors.comOCT 281 min read$BSX

Boston Sci Crashes As Cybersecurity Attack Weighs On Guide

Boston Scientific (BSX) reduced its 2026 outlook due to a cybersecurity incident, now expecting 3.75% organic sales growth and $3.16-$3.18 EPS. The stock fell on the news.

Original reporting
investors.com
Published Oct 28, 2026, 1:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 4:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$BSX
Bearish
high confidence
Mentioned
$BSX
Relevance
8/10
AlphAI data visualization · based on investors.com
Decision brief

The 30-second read

$BSXBearishHigh
01

Why it matters

The guidance downgrade is a primary catalyst that can drive further downside as investors reassess risk and growth expectations.

02

Market read

The news directly affects BSX and may influence sentiment across the broader medical device sector.

03

What to watch

Potential insurance recoveries or cost‑saving measures could mitigate the earnings impact.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Boston Scientific announced a reduced 2026 sales growth outlook (3.75% organic) and EPS guidance ($3.16‑$3.18) after a cyberattack, triggering a sharp share price decline.

Company-level read

Ticker impact

$BSXBearishHigh confidence
Context

Boston Scientific cut its 2026 outlook and lowered EPS guidance after a cybersecurity incident, causing the stock to crash.

Expected impact

likely downward pressure as investors price in weaker growth and earnings

Evidence & confidence

Guidance cuts are a strong, time‑sensitive catalyst; the cyber incident adds risk, making the move immediate.

Market effects

Sector

Medtech sector may face heightened scrutiny on cyber resilience, potentially affecting peers.

Regional

U.S. healthcare stocks could see modest pullback.

Global

Limited to U.S. listed medtech firms; no broad macro effect.

Counterpoint

What could challenge this read

If the cyber breach is contained, the guidance cut may be overly pessimistic, presenting a short‑term buying opportunity.

Key entities

  • Company
    Boston Scientific

    Medtech manufacturer facing a cybersecurity incident.

Read at source← All news

StoryBoston Scientific cuts FY 2026 outlook as cyberattack drags sales and earnings

Also covered by

5 outlets

Related articles

OCT 28
$BSXHighAI 8/10

Boston Scientific cuts 2026 guidance for third time this year

Boston Scientific reported Q3 revenue of $5.14B, up 1.5% YoY, with net income of $582M. The company reduced its 2026 revenue growth forecast to 4.25% from 5.5%-6.5% and adjusted EPS guidance to $3.16-$3.18. Challenges in Watchman and electrophysiology businesses, along with a cyberattack, impacted performance. The stock fell 7% to $42.02. The $14.5B Penumbra acquisition is now expected to close in early 2027.

finance.yahoo.com2 min
OCT 28
$BSXHighAI 8/10

Why Boston Scientific (BSX) shares are plunging today

Boston Scientific (BSX) shares fell 8% after reporting Q3 2026 net sales growth of 1.5% to $5.138B and adjusted EPS of $0.73, in line with estimates. The company cited ongoing efforts to restore operations following a cybersecurity incident. The stock is down 55.7% YTD and 60.1% from its 52-week high.

financialcontent.com2 min
OCT 28
$BSXHighAI 9/10

Boston Scientific Shares Fall 3.5% as Earnings Miss and Lower Guidance Offset Revenue Growth

Boston Scientific (BSX) shares fell 3.5% premarket after Q3 2026 earnings of $0.73 EPS missed estimates of $0.75, while revenue grew 1.5% YoY to $5.14B. Guidance for Q4 and full-year EPS was below expectations, with Q4 sales projected to decline 1-3%. The company cited a cybersecurity incident as a factor in operational challenges. Cardiovascular and MedSurg divisions saw revenue growth, but international performance was mixed.

finance.yahoo.com2 min
OCT 28
$BSXHighAI 8/10

Boston Scientific cuts annual forecast after quarterly profit falls

Boston Scientific (BSX) reported Q3 net sales of $5.14B, up 1.5%, but GAAP net income fell to $582M. Adjusted EPS declined to $0.73. The company lowered its 2026 sales growth forecast to 4.25% and adjusted EPS guidance to $3.16-$3.18. Q4 sales are expected to fall 1-3%. CEO Mike Mahoney cited challenges, including a cybersecurity incident. Cardiovascular division sales rose 1.9%, while Asia-Pacific sales declined 1.1%.

finance.yahoo.com2 min